Form 4: Harrow Inc. CEO of ImprimisRx, John P. Saharek, Exercises Stock Options and Disposes of Shares for Tax Obligations
SEC Form 4 Filing
John P. Saharek, CEO of ImprimisRx, a subsidiary of Harrow Inc., exercised stock options and disposed of shares to cover payroll tax liabilities and the cost to purchase the stock option.
Summary
- On September 11, 2024, John P. Saharek, CEO of ImprimisRx, exercised stock options to acquire 90,000 shares of Harrow Inc. common stock at a price of $7.37 per share.
- Following the transaction, Saharek directly owns 344,803 shares of Harrow Inc. common stock.
- Saharek disposed of 45,140 shares of common stock at $41.37.
- 29,107 shares were withheld by Harrow to satisfy payroll tax liabilities.
- 16,033 shares were withheld to cover the cost of purchasing the stock option.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects insider activity related to stock options and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/01/2015 | Date stock option was granted under the Issuers 2007 Stock Incentive and Awards Plan. |
| 09/11/2024 | Date of transaction: Exercise of stock options and disposition of shares. |
| 02/01/2025 | Expiration date of the stock option. |
| 09/13/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.